Dr. Dulabh Monga, MD
Claim this profileAllegheny General Hospital
Studies Pancreatic Cancer
Studies Cancer
10 reported clinical trials
29 drugs studied
Area of expertise
1Pancreatic Cancer
Stage IV
Stage III
BRCA1 positive
2Cancer
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Dulabh Monga, MD is currently running
Atezolizumab + Multi-Kinase Inhibitor
for Liver Cancer
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic), for which the patient has received treatment in the past (previously treated). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib and lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab with cabozantinib or lenvatinib may kill more tumor cells in patients with liver cancer.
Recruiting1 award Phase 23 criteria
Pembrolizumab + Olaparib
for Pancreatic Cancer
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
Recruiting1 award Phase 237 criteria
More about Dulabh Monga, MD
Clinical Trial Related4 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Dulabh Monga, MD has experience with
- Lenvatinib
- Irinotecan
- Cabozantinib S-malate
- Data Collection
- Quality-of-Life Assessment
- Questionnaire Administration
Breakdown of trials Dulabh Monga, MD has run
Pancreatic Cancer
Cancer
Pancreatic Neuroendocrine Tumors
Neuroendocrine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dulabh Monga, MD specialize in?
Dulabh Monga, MD focuses on Pancreatic Cancer and Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are Stage III.
Is Dulabh Monga, MD currently recruiting for clinical trials?
Yes, Dulabh Monga, MD is currently recruiting for 5 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Dulabh Monga, MD has studied deeply?
Yes, Dulabh Monga, MD has studied treatments such as Lenvatinib, Irinotecan, Cabozantinib S-malate.
What is the best way to schedule an appointment with Dulabh Monga, MD?
Apply for one of the trials that Dulabh Monga, MD is conducting.
What is the office address of Dulabh Monga, MD?
The office of Dulabh Monga, MD is located at: Allegheny General Hospital, Pittsburgh, Pennsylvania 15212 United States. This is the address for their practice at the Allegheny General Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.